Hat mitgewirkt an:
-
Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome
-
Pre-clinical development of HIV resistant genome edited human CD4+ T cells
-
Designer epigenome modifiers enable robust and sustained gene silencing in clinically relevant human cells
-
Preclinical evaluation of a novel TALEN targeting CCR5 confirms efficacy and safety in conferring resistance to HIV‐1 infection